Catalog4 refs
Tirzepatide
MetabolicMetabolic & Weight Lossglp1Weight LossResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
Circulation
Overview
Tirzepatide is a dual agonist, meaning it switches on both the GIP receptor and the GLP-1 receptor with one molecule. GLP-1 activation boosts glucose-dependent insulin release, suppresses glucagon, slows gastric emptying, and reduces appetite through the brain. Adding GIP activation appears to enhance insulin response and improve how fat tissue handles energy, and the combination seems to outperform hitting GLP-1 alone. As with semaglutide, the peptide carries a fatty-acid chain that binds albumin to extend its half-life enough for once-weekly dosing.
Primary Uses
Type 2 diabetes management
Weight management
Appetite suppression and satiety enhancement
Glucose control and insulin secretion
Improving pancreatic beta cell function and insulin sensitivity
Improving lipid profiles
Reducing blood pressure
Cardioprotection
Chronic weight management
Obesity treatment
Blood sugar control
Cardiovascular risk factor improvement
Diabetes and obesity research
GIP/GLP-1 dual agonist pharmacology
Weight-loss outcomes
Cardiometabolic studies
Metabolic dysfunction-associated steatohepatitis (MASH)
Severe obesity management
Metabolic syndrome reversal
Body composition optimization
Insulin resistance improvement
Beta cell preservation
MACE reduction (cardiovascular)
Blood pressure reduction
Lipid profile improvement
Appetite suppression
Type 2 diabetes
Blood glucose reduction
Weight loss
Insulin secretion
Glucagon inhibition
Obstructive sleep apnea
Protocol Reference
Dose
2.5–5.0 mg weekly (up to 7.5 mg)
Frequency
Once Or Twice Weekly, Same Day(s) Each Week
Half-life
~5 Days
Route
Subcutaneous
Evidence
Human Clinical Data Available / Phase 4, FDA Approved / FDA-approved with extensive clinical trial data (SURMOUNT and SURPASS programs) / FDA Approved / FDA-approved (disputed)
Research References· 22
Research Models
HumanMouseRat
Also in Metabolic